The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma

BACKGROUND: Neoadjuvant programmed death receptor-1 (PD-1) inhibitor combined with chemotherapy has been reported to improve the pathological response of locally advanced esophageal squamous cell carcinoma (ESCC), but the systematic report on survival follow-up is quite few. This study we will repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Huilai, Huang, Chao, Li, Jiachen, Zhang, Fan, Gai, Chunyue, Liu, Zhao, Xu, Shi, Wang, Mingbo, Li, Zhenhua, Tian, Ziqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892710/
https://www.ncbi.nlm.nih.gov/pubmed/36741358
http://dx.doi.org/10.3389/fimmu.2022.1100750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892710/
https://www.ncbi.nlm.nih.gov/pubmed/36741358
http://dx.doi.org/10.3389/fimmu.2022.1100750

Ejemplares similares